Product Management used to manage backlogs. In an AI-Native ART, they curate the evidence and hypotheses that shape what the ART pursues.
That sounds like a small change of wording. It isn’t. It changes what the role spends its week on.
What the role was
In core SAFe, Product Management owns the vision, the roadmap and the ART backlog. Its central skill is prioritization: deciding which features to build next, typically using WSJF. The backlog is the instrument.
That made sense when building was expensive. The scarce resource was capacity, so the most important decision was what to spend it on.
What changed
AI-supported development makes building cheaper and learning faster. The scarce resource is no longer capacity. It is confidence — knowing whether something is worth building at all.
The AI Innovation Pipeline is built around that. Teams produce two kinds of output:
- Learning-oriented — experiments and prototypes
- Value-oriented — features and enablers
Teams run waves of experiments and prototypes to test desirability, viability, feasibility and sustainability. After each wave they ask one question: do we have enough confidence to commit to features and enablers? If not, they run another targeted wave.
Someone has to answer that question across the whole ART, not just inside one team. That is the new centre of Product Management.
What curating evidence actually means
Framing the hypotheses. Before work starts, the question it is meant to answer has to be clear. The pipeline’s Discover stage refines intent: the problem the work addresses and the outcome it should produce.
Reading the evidence. The pipeline captures an audit trail of decisions, results and telemetry — what the framework calls Insights and Evidence. An experiment produces evidence about the hypothesis it tested. A released feature produces operational and user telemetry. Product Management turns that into a decision.
Shaping the next PI. The framework names ART Leadership, especially Product Management, as the owner of PI outcomes. Those are drafted from the roadmap, progress against ART outcomes, and insights from recent Sense and Respond events. Curated evidence is the input that makes them more than a wish list.
What it doesn’t mean
The backlog doesn’t disappear. Value-oriented work still has to be prioritized, and WSJF still works where cost of delay can be estimated. The shift is in emphasis: a backlog ranks what to build; curated evidence decides whether it is still worth building.
And Product Management doesn’t make every call. Teams closest to the customer draft their own team outcomes and often see opportunities first. The role supplies the context — clear outcomes and shared evidence — that lets teams decide well on their own.
Three questions for your Product Managers
1. Can you name the hypothesis behind each experiment your ART is running?
2. Where does experiment evidence go once a team has finished with it — and who reads it across the ART?
3. What evidence made it into your last set of draft PI outcomes?
This is one of four pieces on how ART leadership changes in AI-Native SAFe. Read the overview of all four roles.
The world has changed. The leaders who notice will be the ones the next decade is built around. I write on Thursdays at agile-agilist.com.
Sources
- Scaled Agile, Inc. — AI-Native SAFe framework guidance: AI Innovation Pipeline, ART Outcomes, PI Outcome Planning
- Scaled Agile, Inc. — SAFe 6.0: Product Management
